The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study.


Kaplan M. A., Oruc Z., Gumus M., Ozaydm S., ELKIRAN E. T., Dine N. S., ...Daha Fazla

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.24, sa.3, ss.1081-1086, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 3
  • Basım Tarihi: 2019
  • Dergi Adı: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1081-1086
  • Anahtar Kelimeler: paclitaxel, anthracycline, adjuvant, breast cancer, DOXORUBICIN PLUS CYCLOPHOSPHAMIDE, PHASE-III, DOCETAXEL, OUTCOMES, THERAPY, TAXANES, TRIAL
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Purpose: To analyze the reliability and the effectiveness of chemotherapy and prognostic factors for survival in patients with HER2 (human epidermal growth receptor 2) negative early-stage breast cancer treated with adjuvant sequential anthracycline-based chemotherapy and paclitaxel.